Black Diamond Therapeutics (BDTX) Cash from Operations (2019 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Cash from Operations came in at 10232000.0 in Q1 2026, down 119.16% YoY from 53410000.0 in Q1 2025, and down 50.76% on a QoQ basis from 6787000.0 in Q4 2025.
Black Diamond Therapeutics (BDTX) Cash from Operations (2019 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 8 years of Cash from Operations data on file, last reported at 10232000.0 in Q1 2026.
- Quarterly Cash from Operations fell 119.16% year-over-year to 10232000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34028000.0 (down 376.52% YoY) and the FY2025 annual result came in at 29614000.0, up 147.53% from the prior year.
- Cash from Operations eased to 10232000.0 in Q1 2026, from 6787000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 53410000.0 in Q1 2025 to a low of 28600000.0 in Q1 2022.
- A 5-year average of 11454117.65 and a median of 14726000.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2025 — Cash from Operations jumped 351.95% — and 2026, when it sank 119.16%.
- Tracing BDTX's Cash from Operations over 5 years: stood at 21939000.0 in 2022, then soared by 36.39% to 13956000.0 in 2023, then retreated by 7.87% to 15055000.0 in 2024, then soared by 54.92% to 6787000.0 in 2025, then tumbled by 50.76% to 10232000.0 in 2026.
- The last three Cash from Operations figures came in at 10232000.0 (Q1 2026), 6787000.0 (Q4 2025), and 7850000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | -7.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.97 Mn |
| Jun 30, 2026 | -7.97 Mn |
| Mar 31, 2026 | -10.23 Mn |
| Mar 31, 2026 | -10.23 Mn |
| Dec 31, 2025 | -6.79 Mn |
| Dec 31, 2025 | -6.79 Mn |
| Sep 30, 2025 | -7.85 Mn |
| Sep 30, 2025 | -7.85 Mn |
| Jun 30, 2025 | -9.16 Mn |
| Jun 30, 2025 | -9.16 Mn |
| Mar 31, 2025 | 53.41 Mn |
| Mar 31, 2025 | 53.41 Mn |
| Dec 31, 2024 | -15.06 Mn |
| Dec 31, 2024 | -15.06 Mn |
| Sep 30, 2024 | -11.32 Mn |
| Sep 30, 2024 | -11.32 Mn |
| Jun 30, 2024 | -14.73 Mn |
| Jun 30, 2024 | -14.73 Mn |
| Mar 31, 2024 | -21.20 Mn |
| Mar 31, 2024 | -21.20 Mn |